SCHEMBL2929192

SCHEMBL2929192

Cc1cc(C(=O)N2CCN(CCCN(C)C)CC2)ccc1Nc1cncc(-c2cc3cc(F)ccc3[nH]2)n1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SYK P43405 2/20 0.40
ACHE P22303 6/20 0.38
CCNA2 P20248 3/20 0.37
CDK2 P24941 3/20 0.37
TTK P33981 2/20 0.37
AURKB Q96GD4 1/20 0.37
HRH4 Q9H3N8 1/20 0.37
CDK7 P50613 1/20 0.36
CCNH P51946 1/20 0.36
MNAT1 P51948 1/20 0.36
HPGD P15428 1/20 0.36
MRGPRX1 Q96LB2 1/20 0.35
SLC6A4 P31645 3/20 0.35
TLR8 Q9NR97 1/20 0.34
TLR7 Q9NYK1 1/20 0.34
KDR P35968 1/20 0.34
MGLL Q99685 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL2933646 0.96 SYK (0.37) SYKACHECCNA2CDK2TTK
SCHEMBL2927770 0.83 CDK2 (0.47) SYKCCNA2CDK2TTKAURKB
SCHEMBL2928003 0.82 HRH4 (0.42) SYKCCNA2CDK2TTKAURKB
Trifluoroacetic Acid SCHEMBL4890779 0.80 CDK2 (0.43) SYKCCNA2CDK2TTKAURKB
SCHEMBL2933784 0.79 PIM3 (0.42) SYKHPGD
SCHEMBL2930971 0.79 DYRK1A (0.47) CCNA2CDK2TTKHRH4KDR
SCHEMBL2929057 0.78 SYK (0.43) SYKCCNA2CDK2TTKAURKB
SCHEMBL2929271 0.77 KDR (0.43) HRH4TLR8TLR7KDRMGLL
SCHEMBL2930393 0.76 CDK2 (0.44) CCNA2CDK2TTKAURKBHRH4
SCHEMBL14269675 0.76 TTK (0.43) CCNA2CDK2TTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP claimed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US claimed
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
WO-2007147874-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (PUBL) (SE) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039450-A1 Compounds NEK2, CSNK2A3, CSNK2A1 SYK 1798/4885ACHE 2008/4885CCNA2 471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.